AGRX - Agile Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.73
-0.17 (-5.86%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.86
Open2.90
Bid0.00 x 0
Ask0.00 x 0
Day's Range2.72 - 2.91
52 Week Range1.93 - 5.60
Volume92,778
Avg. Volume127,028
Market Cap93.498M
Beta1.93
PE Ratio (TTM)N/A
EPS (TTM)-0.92
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.20
Trade prices are not sourced from all markets
  • Barrons.com24 days ago

    [$$] 3 Biotech Stocks a Pro Is Buying Now

    The last time we checked in with Joseph Edelman, the founder, chief executive and portfolio manager of Perceptive Advisors and its hedge fund, Perceptive Life Sciences, he was buying stocks ahead of the new year. Edelman famously oversaw a 4% gain in 2016 as the biotech sector tumbled 20%. What stocks are Edelman, and his chief investment officer, Adam Stone, buying now?

  • What Should Investors Know About Agile Therapeutics Inc’s (NASDAQ:AGRX) Long Term Outlook?
    Simply Wall St.25 days ago

    What Should Investors Know About Agile Therapeutics Inc’s (NASDAQ:AGRX) Long Term Outlook?

    In December 2017, Agile Therapeutics Inc (NASDAQ:AGRX) released its latest earnings announcement, which indicated company earnings became less negative compared to the previous year’s level – great news for investorsRead More...

  • GlobeNewswirelast month

    New Research: Key Drivers of Growth for At Home Group, Griffon, Mitek, J & J Snack Foods, Lindsay, and Agile Therapeutics — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, March 23, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • Simply Wall St.last month

    Is Agile Therapeutics Inc’s (NASDAQ:AGRX) Balance Sheet A Threat To Its Future?

    While small-cap stocks, such as Agile Therapeutics Inc (NASDAQ:AGRX) with its market cap of US$103.77M, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...

  • GlobeNewswirelast month

    Abstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition

    PRINCETON, N.J., March 14, 2018-- Agile Therapeutics, Inc.,, a women's healthcare company today announced that an abstract related to the Phase 3 SECURE study for AG200-15, an investigational, once-weekly, ...

  • Associated Presslast month

    Agile Therapeutics reports 4Q loss

    The Princeton, New Jersey-based company said it had a loss of 18 cents per share. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • GlobeNewswirelast month

    Agile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

    PRINCETON, N.J., March 12, 2018-- Agile Therapeutics, Inc., a women's healthcare company, today reported financial results for the three months and year ended December 31, 2017 and provided a corporate ...

  • GlobeNewswire3 months ago

    New Research Coverage Highlights Oracle, General Dynamics, Agile Therapeutics, Fidelity Southern, Syros Pharmaceuticals, and MSA Safety Incorporated — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Jan. 24, 2018--. In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • Benzinga4 months ago

    Analyst Remains Confident In Corium Despite Partner's Bad FDA News

    The U.S. Food and Drug Administration sent an unfavorable Complete Response Letter  last week to Agile Therapeutics Inc (NASDAQ: AGRX ) regarding approval for the Twirla contraceptive patch. The letter ...

  • Reuters4 months ago

    FDA declines to approve Agile's contraceptive patch

    Agile Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve the company's contraceptive patch, citing deficiencies related to its adhesion test methods. The health regulator ...

  • Who Are The Largest Shareholders In Agile Therapeutics Inc (NASDAQ:AGRX)?
    Simply Wall St.4 months ago

    Who Are The Largest Shareholders In Agile Therapeutics Inc (NASDAQ:AGRX)?

    In this analysis, my focus will be on developing a perspective on Agile Therapeutics Inc’s (NASDAQ:AGRX) latest ownership structure, a less discussed, but important factor. Ownership structure has been foundRead More...

  • SmarterAnalyst4 months ago

    With FDA Approvals in Sight, Will Synergy Pharmaceuticals and Agile Therapeutics Skyrocket as H.C Wainwright Predicts?

    If H.C. Wainwright analysts are right, a great deal of upside potential hangs in the balance for two biotech players: Synergy Pharmaceuticals Inc (NASDAQ:SGYP) and Agile Therapeutics Inc (NASDAQ:AGRX). With both companies approaching PDUFA dates with destiny, H.C. Wainwright is upbeat on chances for FDA approval, as Synergy eyes a green light in IBS-C and Agile is raring to hit the contraceptive patch market. In reaction, the analyst maintains a Buy rating on Synergy stock while trimming the price target from $8 to $7 to reflect the latest financing move.

  • Is It Too Late To Buy Agile Therapeutics Inc (AGRX)?
    Simply Wall St.5 months ago

    Is It Too Late To Buy Agile Therapeutics Inc (AGRX)?

    Agile Therapeutics Inc (NASDAQ:AGRX), a pharmaceuticals company based in United States, received a lot of attention from a substantial price increase on the NasdaqGM in the over the last fewRead More...

  • Benzinga5 months ago

    Corium Q4 Sales Top Expectations Ahead Of Slew Of Near-Term Catalysts

    Commercial-stage biopharma company Corium International Inc (NASDAQ: CORI ) reported Thursday 19 percent revenue growth for its fiscal year fourth quarter of 2017, while its loss per share narrowed to ...

  • What Investors Should Know About Agile Therapeutics Inc’s (AGRX) Financial Strength
    Simply Wall St.5 months ago

    What Investors Should Know About Agile Therapeutics Inc’s (AGRX) Financial Strength

    While small-cap stocks, such as Agile Therapeutics Inc (NASDAQ:AGRX) with its market cap of USD $150.42M, are popular for their explosive growth, investors should also be aware of their balanceRead More...

  • Zacks Small Cap Research5 months ago

    AGRX: Countdown to Dec. 26, 2017 PDUFA for Twirla®

    The company’s lead candidate product, Twirla® (AG200-15), is a once-weekly low-dose hormonal contraceptive patch that contains the active ingredients ethinyl estradiol (EE, a synthetic estrogen) and levonorgestrel (LNG, a type of progestin). The patch utilizes the company’s Skinfusion technology, which allows Twirla® to be the first contraceptive patch capable of delivering LNG across the skin in a reliable manner. The company has conducted a comprehensive development program for Twirla® that includes three Phase 3 clinical trials.

  • PR Newswire6 months ago

    Agile Therapeutics Presents Additional Phase 3 SECURE Trial Results for Twirla® at the American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo 2017

    PRINCETON, N.J., Oct. 31, 2017 /PRNewswire/ -- Agile Therapeutics, Inc., (AGRX), a women's healthcare company, today announced additional data from its Phase 3 SECURE trial of Twirla® (AG200-15), an investigational, once-weekly, low-dose hormonal contraceptive patch, which showed women experienced mean decreases in length of bleeding and spotting episodes. Over 12 months, women on Twirla reported a gradual decrease in the mean total number of bleeding and/or spotting episodes from 6.0 to 4.9 days from cycles two through 13. Scheduled bleeding, or withdrawal bleeding during the patch-free week, decreased from 4.7 days at cycle two to 4.1 days at the end of the trial.

  • Investopedia6 months ago

    3 Biotech Stocks to Consider Ahead of FDA Decisions

    For investors with a high-risk tolerance, tracking key FDA approval dates for drug candidates is a smart strategy for potentially generating huge returns.

  • Agile Therapeutics Presents Additional Twirla® Phase 3 SECURE Study Results at NAFFP 2017
    PR Newswire6 months ago

    Agile Therapeutics Presents Additional Twirla® Phase 3 SECURE Study Results at NAFFP 2017

    PRINCETON, N.J., Oct. 16, 2017 /PRNewswire/ -- Agile Therapeutics, Inc., (AGRX), a women's healthcare company, today announced the presentation of additional results from the Phase 3 SECURE trial of its investigational low-dose combination hormonal contraceptive patch, Twirla® (AG200-15). Anita Nelson, MD, Professor and Chair of Obstetrics and Gynecology at the College of Osteopathic Medicine of the Pacific, presented new data on the Twirla bleeding profile during a poster presentation at the 2017 National Association for Family Planning (NAFFP), "The Forum" in Atlanta, GA. The poster presentation provided detailed analyses on scheduled (withdrawal) and unscheduled (breakthrough) bleeding and/or spotting episodes.  Rates of unscheduled bleeding and/or spotting decreased during the study period.  Similarly, the mean length of both unscheduled and scheduled bleeding and/or spotting episodes decreased during the study period.  Few subjects discontinued from the trial for bleeding-related issues, and rates of unscheduled bleeding and/or spotting decreased over the 12-month study period.

  • Zacks Small Cap Research6 months ago

    AGRX: Puts Forth Strong Case for Twirla® Ahead of PDUFA on Dec. 26, 2017

    The company’s lead candidate product, Twirla® (AG200-15), is a once-weekly low-dose hormonal contraceptive patch that contains the active ingredients ethinyl estradiol (EE, a synthetic estrogen) and levonorgestrel (LNG, a type of progestin). The patch utilizes the company’s Skinfusion technology, which allows Twirla® to be the first contraceptive patch capable of delivering LNG across the skin in a reliable manner. On October 10, 2017, Agile hosted an analyst day and provided a comprehensive overview of Twirla®, including a full discussion of the data from the Phase 3 SECURE trial in the context of other clinical and real world data seen with other combination hormonal contraceptive products.